EU Approves Sanofi’s (SNY) Sarclisa for Newly Diagnosed Multiple Myeloma Patients
Sanofi (NASDAQ:SNY) ranks among the best medical stocks to buy according to analysts.
Sanofi Aventis (SNY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 13,135,366 | $634,569,599 | -4% | 0.25% |
| 2. | VGI Partners Robert M. P. Luciano | 1,548,204 | $74,793,735 | +103% | 6.32% |
| 3. | Alyeska Investment Group Anand Parekh | 621,417 | $30,020,655 | +341% | 0.11% |
| 4. | Callodine Capital Management James Morrow | 515,209 | $24,889,747 | +27% | 2.58% |
| 5. | 461,200 | $22,280,572 | +594% | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 71,718,315 | $3,464,711,798 | 1.95% | |
| 2. | 9,998,529 | $483,028,922 | 0.04% | |
| 3. | 9,188,204 | $443,882,147 | 0.08% | |
| 4. | 8,354,084 | $403,585,798 | 0.06% | |
| 5. | 7,280,536 | $351,722,695 | 1.19% |
News See All
Sanofi (NASDAQ:SNY) Q2 2025 Earnings Call Transcript
Thomas Kudsk Larsen: Hello, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q2 2025 conference call for investors and analysts.
11 Best Medical Stocks to Buy According to Analysts
As macroeconomic headwinds, regulatory reforms, and geopolitical concerns converge in the second half of 2025, PwC predicts that the health industry's resilience and adaptability will be put to the test...
Sanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal
Sanofi (NASDAQ:SNY), a global biopharmaceutical leader headquartered in France with about 83,000 employees, is focused on immunology, oncology, rare diseases, and vaccines.
10 Most Undervalued Pharma Stocks to Buy Now
Pharmaceutical manufacturing in the U.S. has declined sharply over recent decades, with most active ingredient production shifting overseas due to lower labor costs. In 2023, the U.S.
FDA Grants Orphan Drug Designation To Sanofi's (SNY) Riliprubart
Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) announced that the FDA granted orphan drug designation to Riliprubart for treating...
Sanofi's (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in Japan
Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that its Riliprubart has been granted orphan drug designation in Japan for chronic...
11 Best 52-Week Low Stocks to Buy Right Now
On July 2, Tom Lee, Fundstrat's Head of Research and CIO, joined CNBC Television to discuss market conditions. He noted that the investors remain skeptical despite strong market gains.
10 Best Dip Stocks to Buy According to Billionaires
On July 3rd, Dan Ives, Global Head of Tech Research at Wedbush, joined CNBC to discuss the technology sector.
Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
Sanofi (NASDAQ:SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds.